[Control of viral hepatitis in Lithuanian hemodialysis centers in 1997-2001].
Hemodialysis patients are a high-risk group for hepatitis B and C virus infections. The aim of the study was to evaluate the prevalence of B and C viral hepatitis, level of its control among patients on hemodialysis. In December of 1997, 1998, 1999, 2000, 2001 we visited all hemodialysis centers of Lithuania and gathered information about these infections in patients on hemodialysis. Eleven percent (11.4%) of all hemodialysis patients were not examined for HB(s)Ag and 15.2% for anti-HCV, 67.3%--for anti-HB(s) and 57.7% for anti-HBc in 2001. The number of examined patients for the markers of hepatitis had increased in 2001 in comparison with 1997. The same number of hemodialysis patients with HB(s)Ag was found in each year of study (14% in 1997, 14.4% in 2001). We observed the decrease in percentage of anti-HCV positive patients from 23% in 1998 till 15.4% (p<0.01) in 2001. Only 10.6% hepatitis B virus vaccinated patients was registered in 2001 and this percentage increased if compared to 6.3% in 1999. About (1/4) of anti-HB(c) positive patients were HB(s)Ag positive in 2000-2001. Chronic hepatitis B could be diagnosed for them. The duration of hemodialysis of HB(s)Ag and anti-HCV positive patients was longer compared to HB(s)Ag and anti-HCV negative patients (p<0.001).
Ziginskiene
Edita
E
Clinic of Nephrology, Kaunas University of Medicine, Kaunas, Lithuania.
Kuzminskis
Vytautas
V
Kupcinskas
Limas
L
Stankuviene
Asta
A
D003627:Data Interpretation, Statistical; D006509:Hepatitis B / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008097:Lithuania / Q000453:epidemiology; D015995:Prevalence; D006435:Renal Dialysis; D012307:Risk Factors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D014761:Viral Hepatitis Vaccines